Changes in overall survival over time for patients with de novo metastatic breast cancer

Toshiaki Iwase 1,2, Tushaar Vishal Shrimanker 1,2, Ruben Rodriguez-Bautista 1,2, Onur Sahin 1,2, Anjali James 1,2, Jimin Wu 3, Yu Shen 3, and Naoto T. Ueno 1,2*

1 Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA; tiwase@mdanderson.org (T.I.); tushaar.shrimanker@greenwichhospital.org (T.V.S); rrodriguez15@mdanderson.org (R.R.B.); osahin1@mdanderson.org (O.S.); ajames2@mdanderson.org (A.J.); nueno@mdanderson.org (N.T.U.)
2 Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA; jwu5@mdanderson.org (J.W.); yshen@mdanderson.org (Y.S.)
4 Correspondence: nueno@mdanderson.org; Tel.: +1-713-792-8754; FAX: +1-888-375-2139

Simple Summary: The aim of the present study was to clarify the change in survival for de novo metastatic breast cancer over time. We found that overall survival significantly improved over time for the estrogen-receptor-positive, HER2-positive subtype and exhibited a tendency toward improvement over time for the estrogen-receptor-negative, HER2-positive subtype. These results underscored the contribution of HER2-targeted therapy to survival.

Abstract: The purpose of this study was to determine the change in overall survival (OS) for patients with de novo metastatic breast cancer (dnMBC) over time. We conducted a retrospective cohort study with 1981 patients with dnMBC diagnosed between January 1995 and December 2017 at The University of Texas MD Anderson Cancer Center. OS was measured from the date of diagnosis of dnMBC. OS was compared between patients diagnosed during different time periods: 5-year periods and periods defined according to when key agents were approved for clinical use. The median OS was 3.4 years. The 5- and 10-year OS rates improved over time across both types of time periods. A subgroup analysis showed that OS improved significantly over time for the estrogen-receptor-positive/HER2-positive (ER+/HER2+) subtype, and exhibited a tendency toward improvement over time for the ER-negative (ER-)/HER2+ subtype. Median OS was significantly longer in patients with non-inflammatory breast cancer (P = .02) and in patients with ER+ disease, progesterone-receptor-positive disease, HER2+ disease, lower nuclear grade, locoregional therapy, and metastasis to a single organ (all P <.0001). These findings showed that OS at 5 and 10 years after diagnosis in patients with dnMBC improved over time. The significant improvements in OS over time for the ER+/HER2+ subtype and the tendency toward improvement for ER-/HER2+ subtype suggest the contribution of HER2-targeted therapy to survival.

Keywords: Breast neoplasms; neoplasm metastasis; inflammatory breast neoplasms; survival analysis

1. Introduction

De novo metastatic breast cancer (dnMBC) is breast cancer that manifests metastasis at the time of initial diagnosis; dnMBC is different from recurrent metastatic breast cancer (rMBC). In the US, dnMBC accounted for approximately 6% of all breast cancer cases between 2005 and 2011 [1].

A previous retrospective study that compared clinical characteristics between patients with dnMBC and rMBC showed that patients with dnMBC tended to have higher rates of hormone receptor-negative disease, bone metastasis, and liver metastasis and a...
lower rate of central nervous system metastasis [2]. In a survival analysis of 643 patients with dnMBC and 2881 with rMBC, the dnMBC patients had longer median overall survival (OS) (39.2 months vs. 27.2 months) [3]. Plausible reasons for the better OS of patients with dnMBC include that 1) dnMBC is chemonaïve, and a lower percentage of patients with dnMBC than with rMBC had originally chemo-resistant disease, and 2) general clinical characteristic of dnMBC patients is dormant such as bone-only metastasis and oligometastasis.

Although dnMBC differs clinically from rMBC, the general treatment strategy for dnMBC follows the rMBC treatment algorithm. In rMBC, the introduction of newly developed chemotherapy and targeted therapy has contributed to improvement in survival over time. For instance, the introduction of drugs targeting human epidermal growth factor receptor 2 (HER2) drastically improved the survival of patients with rMBC [4]. However, little is known about how advances in treatment have changed survival for patients with dnMBC. Moreover, the impact of biological features and locoregional interventions on survival in patients with dnMBC needs to be elucidated. Clarifying these unknowns will contribute to a better understanding of dnMBC’s biology and will guide future research directions.

We hypothesized that the OS of patients with dnMBC has improved over time along with the development in drug therapy. The primary objective of this study was to test our hypothesis. The secondary objective was to identify biological and clinical prognostic factors for dnMBC.

2. Materials and Methods

2.1. Inclusion criteria

This was a retrospective cohort study with prospectively collected data designed to determine the change in OS over time for dnMBC. We defined dnMBC as breast cancer with histologically proven distant metastasis at the time of initial diagnosis. Using this definition of dnMBC, we retrospectively searched the Breast Cancer Electronic Medical Record Management System at The University of Texas MD Anderson Cancer Center for patients diagnosed with dnMBC during the period from January 1995 through December 2017. This search identified 2737 potentially eligible patients with dnMBC (Figure 1). Of these patients, 576 patients were excluded because of insufficient pathological information, including data on estrogen receptor (ER) status, progesterone receptor (PR) status, HER2 status, and grade. An additional 180 patients were excluded because of lack of information about inflammatory breast cancer (IBC, N = 148), locoregional therapy (N = 30), or site of metastasis (N = 2). In total, 1981 patients with dnMBC were eligible for analysis. The primary outcome was OS, which was defined as the time from the date of the initial diagnosis until the date of death from any cause. The patient’s time to death was censored at last follow-up if the patient was alive without an event occurrence at the last follow-up.
2.2. Definition of time periods

To determine the changes in OS over time, two types of time periods were used: 1) time periods based on the date of approval of key agents by the U.S. Food and Drug Administration (FDA) and 2) 5-year periods. The key agents were trastuzumab, approved in 1999; fulvestrant, approved in 2002; ado-trastuzumab emtansine, approved in 2013; and pertuzumab, approved in 2013. For triple-negative breast cancer (TNBC), PARP inhibitors were potential key drugs; however, we excluded PARP inhibitors because their potential to contribute to OS improvement seemed limited given the low prevalence of BRCA1 and BRCA2 mutations in previous reports [5-7].

2.3. Definitions of clinical and pathological variables

Cases of dnMBC were defined as positive for ER or PR if at least 1% of cells expressed the hormone receptor by immunohistochemistry (IHC). HER2 positivity was determined according to the American Society of Clinical Oncology/College of American Pathologists guidelines at the time of pathological evaluation. IBC was a clinical diagnosis made by a multidisciplinary team consisting of a medical oncologist, surgical oncologist, radiologist, and nurse; IBC was diagnosed when patients exhibited one or more of a set of specific clinical manifestations, including history of rapid onset of breast erythema, edema and/or peau d’orange, and/or warm breast, with or without an underlying palpable mass. A history of flattening, crusting, or retraction of the nipple were also considered. Locoregional treatment was defined as surgical resection of the primary tumor by any method and radiation therapy delivered to the area of the breast and regional lymph nodes regardless of the dose and the frequency of the treatment. Metastasis to a single organ was defined as metastasis in only one organ, such as bone, lung, brain, or soft tissue, including distant lymph nodes (but not regional lymph nodes), confirmed by imaging and pathology. Patients with multiple sites of metastasis in the same organ were considered to have metastasis to a single organ if that was the only organ involved.

2.4. Statistical considerations

Data were summarized using standard descriptive statistics, such as mean, standard deviation, median, and range for continuous variables and frequency and proportion for categorical variables. OS duration was estimated using the Kaplan-Meier method, and
OS was compared between or among groups by using the log-rank test. Univariate and multivariate Cox regression models were applied to assess the effect of variables of interest on OS. The model was selected by the backward method. We considered two-sided P <.05 significant. All computations were carried out in SAS 9.4 (SAS Institute Inc., Cary, NC, USA). The study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center before data collection was initiated (protocol number: PA17-0613).

3. Results

3.1. Patient characteristics

Table 1 shows the clinical characteristics of the patients included in the study. The median age was 52 years. Approximately 70% of the patients had ER-positive (ER+) disease, and 28% had HER2-positive (HER2+) disease. Fifteen percent of the patients had TNBC. Seventeen percent of the patients had IBC. Thirty-nine percent of the patients received locoregional therapy, and 62% had metastasis to a single organ.

Table 1. Patient characteristics (N = 1981)

| Characteristic                     | Number of patients (%) |
|-----------------------------------|------------------------|
| Year of diagnosis, grouping 1     |                        |
| 1995-1998                         | 72 (4)                 |
| 1999-2003                         | 305 (15)               |
| 2004-2008                         | 469 (24)               |
| 2009-2012                         | 564 (29)               |
| 2013-2017                         | 571 (29)               |
| Year of diagnosis, grouping 2     |                        |
| 1995-1999                         | 100 (5)                |
| 2000-2004                         | 353 (18)               |
| 2005-2009                         | 517 (26)               |
| 2010-2014                         | 676 (34)               |
| 2015-2017                         | 335 (17)               |
| Age at diagnosis, median (range), year | 52 (22-93)           |
| ER status                         |                        |
| Positive                          | 1398 (71)              |
| Negative                          | 580 (29)               |
| Unknown                           | 3                      |
| PR status                         |                        |
| Positive                          | 1051 (53)              |
| Negative                          | 920 (47)               |
| Unknown                           | 10                     |
| HER2 status                       |                        |
| Positive                          | 555 (28)               |
| Negative                          | 1426 (72)              |
| Subtype                           |                        |
| ER+/HER2+                         | 330 (17)               |
| ER+/HER2-                         | 1120 (57)              |
| ER-/HER2+                         | 225 (11)               |
| TNBC                              | 306 (15)               |
| Nuclear grade                     |                        |
| 1                                 | 96 (5)                 |
| 2                                 | 754 (38)               |
| 3                                 | 1131 (57)              |
3.2. OS by disease and treatment characteristics

The median follow-up time was 7.4 years (95% confidence interval [CI]: 6.99-8.22). A total of 1365 of the 1981 patients died by the end of the study period. The median OS interval was 3.4 years (95% CI: 3.18-3.64) (Supplementary Figure 1). The median OS interval was significantly longer in patients with non-IBC (vs. IBC) ($P = .0210$); median OS was also significantly longer in patients with ER+ disease (vs. ER-), PR+ disease (vs. PR negative [PR-]), HER2+ disease (vs. HER2-), lower nuclear grade, locoregional therapy (vs. none), and metastasis to a single organ (vs. multiple organs) (all $P < .0001$) (Supplementary Figure 2A-D, F-H). The Kaplan-Meier curves crossed at around 7 years for IBC (Supplementary Figure 2A), 10 years for ER (Supplementary Figure 2B), and 10 years for PR (Supplementary Figure 2C). The ER+/HER2- subtype was associated with a better prognosis than the ER-/HER2+ subtype until 5 years after diagnosis when the curves crossed (Supplementary Figure 2E). The survival curves of the ER-/HER2+ subtype and TNBC subtype plateaued after 5 years, but the survival curves of the ER+/HER2- subtype and ER+/HER2+ subtype kept declining after 5 years (Supplementary Figure 2E).

3.3. Prognostic factors for OS

Table 2 shows the results of the univariate and multivariate Cox regression models with the primary outcome of OS. The univariate analysis demonstrated that subtype, nuclear grade, locoregional therapy, and number of organs with metastasis were significantly associated with OS. When other variables of interest were adjusted, the patients with ER+/HER2- subtype had a 71% higher risk of death than those with ER+/HER2+ subtype, and the patients with ER-/HER2+ subtype had a 49% higher risk of death than those with ER+/HER2+ subtype. Furthermore, the patients with TNBC had almost 4 times the risk of death in those with ER+/HER2+ disease. The patients with grade 3 disease had a 74% higher risk of death than those with grade 1 disease. The patients who received locoregional therapy had a 50% lower risk of death than those without locoregional therapy. The patients with metastasis to a single organ had a 36% lower risk of death than those with metastasis to multiple organs.

| Variables                          | HR (95% CI) | P-value | HR (95% CI) | P-value |
|------------------------------------|-------------|---------|-------------|---------|
| Year of diagnosis, grouping 1      | 1995-1998 vs. 2013-2017 | 1.12 (.85-1.48) | .4117 |
| Year of diagnosis, grouping 2 | OS rate (%)  |
|-------------------------------|-------------|
| 1995-1999 vs. 2000-2004       | .91 (.72-1.15) |
| 2005-2009 vs. 2000-2004       | .8 (.69-.93)   |
| 2010-2014 vs. 2000-2004       | .91 (.78-1.05) |
| 2015-2017 vs. 2000-2004       | .88 (7.1-1.1)  |

3.4. Changes in OS over time

Figure 2 shows the OS rates for patients with dnMBC by diagnosis date, with dates grouped according to the timing of approval of key drugs (Figure 2A) and 5-year periods (Figure 2B). In both analyses, the 5-year and 10-year OS rates tended to improve over time, whereas the 1-year and 2-year OS rates did not. In the analysis based on the timing of approval of key drugs, the 5-year OS rate improved from 35% (95% CI: 24%-46%) for patients diagnosed in 1995-1998 to 38% (95% CI: 32%-44%) for those diagnosed in 2013-2017, and the 10-year OS rate improved from 8% (95% CI: 3%-16%) for patients diagnosed in 1995-1998 to 17% (95% CI: 14%-21%) for those diagnosed in 2004-2008. In the analysis based on 5-year periods, the 5-year OS rate improved from 33% (95% CI: 24%-42%) for patients diagnosed in 1995-1999 to 43% (95% CI: 33%-52%) for those diagnosed in 2015-2017, and the 10-year OS rate improved from 11% (95% CI: 6%-18%) for patients diagnosed in 1995-1999 to 18% (95% CI: 14%-21%) for those diagnosed in 2005-2009.
The timing of approval of key drugs

Figure 2. Overall survival rates for patients with de novo metastatic breast cancer at 1, 2, 5, 10, and 15 years after diagnosis according to diagnosis date, with dates grouped according to (a) the timing of approval of key drugs and (b) 5-year periods.

Next, we investigated the change in OS over time stratified by breast cancer subtype. We did not observe any significant change in OS over time for ER+/HER2- subtype or TNBC (Figure 3A, 3D). In contrast, OS for the ER+/HER2+ subtype significantly improved over time (Figure 3B). Although the result was not statistically significant, OS for the ER-/HER2+ subtype tended to improve over time (Figure 3C).

Figure 3. Overall survival curves for patients with de novo metastatic breast cancer according to year of diagnosis and breast cancer subtype: (a) estrogen receptor positive and HER2 negative (ER+/HER2-); (b) ER+/HER2 positive (HER2+); (c) ER-negative/HER2+; and (d) triple-negative breast cancer.

4. Discussion

The present study showed that the 5-year and 10-year OS rates for patients with dnMBC exhibited a tendency toward improvement over time across time periods defined according to the dates of approval of key agents and across 5-year periods. OS improved significantly over time in the ER+/HER2+ subtype and exhibited a tendency toward improvement over time in the ER-/HER2+ subtype. Furthermore, we identified biological and clinical prognostic factors for dnMBC, including IBC status, ER status, PR status, HER2 status, subtype, nuclear grade, locoregional therapy, and number of organs with metastasis.
Consistent with the results of a previous study of dnMBC versus rMBC [8], our study showed a tendency toward improvement in OS over time for dnMBC [8]; however, this was observed only 5 and 10 years after diagnosis. This result underscores the difficulty of improving the survival outcome for patients with dnMBC with progression within 2 years after diagnosis. Our analysis revealed that many of the deaths within 2 years were in patients with TNBC, a subtype that did not show a significant improvement in OS over time.

TNBC does not have a specific druggable target. The PARP inhibitors could be a candidate for treatment of TNBC; however, we estimated the contribution in terms of improving OS would be limited because the prevalence of BRCA1/2 mutations in TNBC is approximately 10% to 20% in unselected cohorts [5-7]. A recent breakthrough in treatment of metastatic TNBC is the use of an immune checkpoint inhibitor. The IMpassion130 trial showed that in patients with metastatic TNBC, PD-L1 blockade prolonged OS by approximately 4 months compared to OS in the control group [9]. Moreover, the subgroup of patients positive for PD-L1 by IHC demonstrated an improvement in OS of approximately 10 months with immune checkpoint inhibitor treatment. The survival benefit of immunotherapy with ICI is still under investigation in ongoing clinical trials, and the definitive results are expected to be available within the next 5 years. Given the current situation of drug development for treatment of metastatic TNBC, we expect that the novel treatment of dnMBC will contribute to the improvement of survival outcomes for TNBC in the next few years.

The subgroup analysis showed significant OS improvement for the ER+/HER2+ subtype and a tendency toward OS improvement for the ER-/HER2+ subtype over time. The OS improvement in HER2+ disease was due to the development of HER2-targeted drugs, especially trastuzumab and pertuzumab. Those HER2-targeted drugs have revolutionized the treatment of HER2+ breast cancer and significantly prolonged survival. A systematic review of the efficacy of trastuzumab-containing regimens showed that they significantly decreased the HR for both death (HR, .82; 95% CI, .71-.94; P = .004) and disease progression (HR, .61; 95% CI-.54, .70; P <.00001) [4]. Moreover, the combination of trastuzumab and pertuzumab with docetaxel prolonged OS approximately 16 months compared with the placebo combination group [10]. In contrast to the efficacy of HER2-targeted drugs against HER2+ breast cancer, the efficacy of fulvestrant against ER+ and/or PR+ MBC was limited to improvements in disease progression; fulvestrant as monotherapy improved median progression-free survival by approximately 3 months [11]. However, the combination of fulvestrant with CD4/6 inhibitor showed a significant improvement of OS, with HRs of .746 and .71, respectively, in the MONALEESA-2 and MONALEESA-7 trials [12,13]. Since the FDA approved CD4/6 inhibitor for treatment of metastatic hormone-receptor-positive breast cancer in 2015, we could not evaluate the survival effect of CD4/6 inhibitor in the present study. An updated analysis after the next 5 years will be needed to evaluate the survival effect of CD4/6 inhibitor in the real world.

As we expected, the clinical prognostic factors for dnMBC in the present study — subtype, nuclear grade, locoregional therapy, and number of organs with metastasis—were consistent with those previously reported [14,15]. Intriguingly, we observed that the survival curves for patients stratified by ER status and PR status crossed around 10 years. The survival curves of ER+ and PR+ groups kept declining and crossed the comparison group around 10 years after diagnosis. This result could be partly due to the acquired resistance to endocrine therapy during the long course of endocrine treatment. Once a tumor has acquired resistance, selection of effective treatment becomes very difficult, and the survival outcome would be poor. In the present study, hormone-receptor-positive dnMBC had better survival outcome than HER2+ dnMBC at baseline; however, overcoming resistance will be the key to further improve the survival outcome for the hormone-receptor-positive subgroup. The multivariate analysis also showed that
locoregional therapy and number of organs with metastasis were prognostic factors. The efficacy of locoregional therapy for the primary tumor in patients with dnMBC has been discussed extensively. To date, three randomized clinical trials have been performed to answer the clinical question. A study from India with 716 patients with dnMBC found no survival benefit from early locoregional therapy [16], whereas a study by the Turkish Federation showed an improvement of OS by 17% with locoregional therapy [17]. The latest results of a large phase III randomized clinical trial with 256 patients with dnMBC showed that locoregional therapy for the primary tumor did not significantly improve OS (3-year OS rate, 68.4% for the locoregional therapy group vs. 67.9% for the non-locoregional therapy group; P = .63 by log-rank test) [18]. Given those results, the impact of locoregional therapy on the primary tumor on survival appears to be limited; however, the benefit of locoregional therapy for controlling local disease progression should be investigated to improve the patient quality of life.

Limitations

The present study has several limitations. First, we excluded 756 of 2737 initially screened patients because of a lack of necessary pathological information. This process might have introduced a selection bias and affected the results. Second, we did not investigate the use of key drugs in each patient and did not evaluate the direct association between drug use and change in OS. Last, the methods of pathological evaluation, including the type of antibody, IHC procedure, and evaluation methods, were not standardized throughout the study period. To overcome these limitations, a detailed evaluation via a well-designed prospective study would be crucial.

5. Conclusions

In this large retrospective cohort study, we confirmed that dnMBC exhibited a tendency toward improvement in OS over time, especially at the timepoints of 5 and 10 years after diagnosis. Although the improvement was not large, the significant OS improvement in the ER+/HER2+ subtype and the tendency toward OS improvement in the ER-/HER2+ subtype suggested the contribution of HER2-targeted therapy. The biological and clinical prognostic factors for dnMBC were similar to those described in previous reports; however, further investigation will be needed to elucidate the biology of dnMBC.

Author Contributions: Conceptualization, N.T.U., T.I.; methodology, N.T.U., T.I., J.W., Y.S.; software, J.W., Y.S.; validation, J.W., Y.S.; formal analysis, J.W., Y.S.; investigation, T.I., T.S.V., R.R.B.; resources, T.I.; data curation, T.I., T.S.V., R.R.B., O.S., A.J.; writing—original draft preparation, T.I.; writing—review and editing, Y.S., T.V.S., R.R.B, N.T.U.; visualization, T.I., J.W., Y.S.; supervision, Y.S., N.T.U.; project administration, N.T.U.; funding acquisition, N.T.U. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by the Morgan Welch Inflammatory Breast Cancer Research Program, a State of Texas Rare and Aggressive Breast Cancer Research Program grant, National Institutes of Health/National Cancer Institute award 1R01CA205043-01A1 (to N.T.U.).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center before the data collection was initiated (protocol number: PA17-0613).

Informed Consent Statement: Patient consent was waived due to the retrospective study design.

Data Availability Statement: The data of present study is not publicly available.

Acknowledgments: The authors thank Stephanie P. Deming for editing the manuscript (Research Medical Library, The University of Texas MD Anderson Cancer Center), Limin Hsu and Modesto G. Patangan, Jr, for data collection (Breast Medical Oncology, The University of Texas MD Anderson
Cancer Center), and Huiming Sun for protocol development (Breast Medical Oncology, The University of Texas MD Anderson Cancer Center).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Howlader N, A.F., Krapcho M. SEER cancer statistics review, 1975–2012. Available online: http://seer.cancer.gov/csr/1975_2012/ (accessed on
2. Tripathy, D.; Brufsky, A.; Cobleigh, M.; Jahanzeb, M.; Kaufman, P.A.; Mason, G.; O’Shaughnessy, J.; Rugo, H.S.; Swain, S.M.; Yardley, D.A.; et al. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. The oncologist 2020, 25, e214-e222, doi:10.1634/theoncologist.2019-0446.
3. Dawood, S.; Broglio, K.; Ensor, J.; Hortobagyi, G.N.; Giordano, S.H. Survival differences among women with de novo stage IV and relapsed breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2010, 21, 2169-2174, doi:10.1093/annonc/mdq220.
4. Balduzzi, S.; Mantarro, S.; Guaneri, V.; Tagliabue, L.; Pistotti, V.; Moja, L.; D’Amico, R. Trastuzumab-containing regimens for metastatic breast cancer. The Cochrane database of systematic reviews 2014, 2014, Cd006242, doi:10.1002/14651858.CD006242.pub2.
5. Gonzalez-Angulo, A.M.; Timms, K.M.; Liu, S.; Chen, H.; Litton, J.K.; Potter, J.; Lanchbury, J.S.; Stemke-Hale, K.; Hennessy, B.T.; Arun, B.K.; et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2011, 17, 1082-1089, doi:10.1158/1078-0432.Ccr-10-2560.
6. Hartman, A.R.; Kaldate, R.R.; Sailer, L.M.; Painter, L.; Grier, C.E.; Endsley, R.R.; Griffin, M.; Hamilton, S.A.; Frye, C.A.; Silberman, M.A.; et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 2012, 118, 2787-2795, doi:10.1002/1050-962X.CND.26576.
7. Wong-Brown, M.W.; Meldrum, C.J.; Carpenter, J.E.; Clarke, C.L.; Narod, S.A.; Jakubowska, A.; Rudnicka, H.; Lubinski, J.; Scott, R.J. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast cancer research and treatment 2015, 150, 71-80, doi:10.1007/s10549-015-3293-7.
8. Malmgren, J.A.; Mayer, M.; Atwood, M.K.; Kaplan, H.G. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010. Breast cancer research and treatment 2018, 167, 579-590, doi:10.1007/s10549-017-4529-5.
9. Schmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Hegg, R.; Im, S.-A.; Shaw Wright, G.; et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine 2018, 379, 2108-2121, doi:10.1056/NEJMoa1809615.
10. Swain, S.M.; Baselga, J.; Kim, S.-B.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.-M.; Schneeweiss, A.; Heeson, S.; et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine 2015, 372, 724-734, doi:10.1056/NEJMoa1413513.
11. Robertson, J.F.R.; Bondarenko, I.M.; Trishkina, E.; Dvorkin, M.; Panasci, L.; Manikhas, A.; Shparyk, Y.; Cardona-Huerta, S.; Cheung, K.-L.; Philco-Salas, M.; et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet 2016, 388, 2997-3005, doi:10.1016/S0140-6736(16)32389-3.
12. Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y.S.; Sonke, G.S.; Paluch-Shimon, S.; Campone, M.; Petراكova, K.; Blackwell, K.L.; Winer, E.P.; et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2018, 29, 1541-1547, doi:10.1093/annonc/mdy155.
13. Im, S.-A.; Lu, Y.-S.; Bardia, A.; Harbeck, N.; Colleoni, M.; Franke, F.; Chow, L.; Sohn, J.; Lee, K.-S.; Campos-Gomez, S.; et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. *New England Journal of Medicine* 2019, 381, 307-316, doi:10.1056/NEJMoai1903765.

14. Zeichner, S.B.; Herna, S.; Mani, A.; Ambros, T.; Montero, A.J.; Mahtani, R.L.; Ahn, E.R.; Vogel, C.L. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. *Breast cancer research and treatment* 2015, 153, 617-624, doi:10.1007/s10549-015-3564-3.

15. Lane, W.O.; Thomas, S.M.; Blitzblau, R.C.; Plichta, J.K.; Rosenberger, L.H.; Fayanju, O.M.; Hyslop, T.; Hwang, E.S.; Greenup, R.A. Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis. *Annals of surgery* 2019, 269, 537-544, doi:10.1097/sla.0000000000002621.

16. Badwe, R.; Hawaldar, R.; Nair, N.; Kaushik, R.; Parmar, V.; Siddique, S.; Budrukkar, A.; Mittra, I.; Gupta, S. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. *The Lancet. Oncology* 2015, 16, 1380-1388, doi:10.1016/s1470-2045(15)00135-7.

17. Soran, A.; Ozmen, V.; Ozbas, S.; Karanlik, H.; Muslimanoglu, M.; Igci, A.; Canturk, Z.; Utkan, Z.; Ozaslan, C.; Evrensel, T.; et al. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. *Annals of surgical oncology* 2018, 25, 3141-3149, doi:10.1245/s10434-018-6494-6.

18. Khan, S.A.; Zhao, F.; Solin, L.J.; Goldstein, L.J.; Cella, D.; Basik, M.; Golshan, M.; Julian, T.B.; Pockaj, B.A.; Lee, C.A.; et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). *Journal of Clinical Oncology* 2020, 38, LBA2-LBA2, doi:10.1200/JCO.2020.38.18_suppl.LBA2.